The European League Against Rheumatism (EULAR) [72] recommends prophylactic treatment with LDA in asymptomatic SLE patients with a ‘high-risk’ aPL profile (defined as the presence of persistent LA, double or triple aPL positivity, and persistent high aPL titre) with or without traditional risk factors. Here, FASLG is linked to systemic lupus erythematosus.